About This Webinar
This presentation will discuss clinical diagnostic tools for dementia and more specifically Alzheimer’s disease.

After some background on Alzheimer’s disease, application of diagnostic tools will be discussed sequentially and also applied on case descriptions.

After this presentation, attendees will know what diagnostic tools are used in memory clinics and how they can be applied.


Kindly supported by Roche

About Roche

Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. We have created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. In the UK we employ over 2,000 people who work hard every day to bring our medicines and diagnostics to people who urgently need them. We work from bench to bedside - researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of our products and services.

For more information: www.roche.co.uk

  • 15.10-15.40 | 'In Conversation With' Professor Nick Fox
  • 15.40-16.10 | Can we really slow down the progression of Alzheimer's disease? Dr Naji Tabet
  • 16.25-16.55 | Types of dementia - Dr Richard Perry
  • 16.55-17.15 | ROCHE | The utility of ALZ biomarkers in clinical routine - Dr Femke Bouwmann
  • 17.15-18.15 | What will be the impact of Covid-19 on the future of dementia care?
  • 18.15-18.45 | Summary of the latest research in imaging - Professor Clare MacKay
  • 1614769859-80d55a3a7b12a019
    Dr Femke Bouwman
    Neurologist, Alzheimer Centre Amsterdam
    Femke Bouwman MD PhD, defended her thesis on ‘CSF biomarkers in dementia: Longitudinal aspects and combination with MRI’ in 2008 and has since been working as Neurologist and staff member of Catharina Hospital Eindhoven and Alzheimer Center VUMC in Amsterdam. She has a special interest and (inter)national expertise in the clinical application of Alzheimer’s Disease (AD) biomarkers. She reinforced her dedication to biomarkers by initiating projects that aim to yield new AD biomarkers (e.g in pathology and retina). She is otherwise involved in many national and international projects in the Alzheimer Center Amsterdam involving biomarker research including amyloid and tau PET imaging and CSF biomarkers. She is initiator and chair of the National Memory clinic Network in the Netherlands. She is founder and chair of the Eye as a biomarker for AD PIA (=professional interest area AAIC) and chairs the Atypical AD PIA. She is member of the Scientific Panel Dementia and Cognitive Disorders of the EAN (European Academy of Neurology).